Search research articles
Contact Us
Filters
Showing results (121-130 of 160) with videos related to
Page
of 16
Sort By:
Molecular Pharmaceutics
|
January 16, 2024
Performance and Sensitivity of [<sup>99m</sup>Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver
Irene Hernández-Lozano, Sarah Leterrier, Severin Mairinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2011
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake
Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 16, 2019
In vivo characterization of [<sup>18</sup>F]AVT-011 as a radiotracer for PET imaging of multidrug resistance
Pavitra Kannan, András Füredi, Sabina Dizdarevic, et al.
Clinical Pharmacology and Therapeutics
|
September 23, 2020
Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects
Martin Bauer, Karsten Bamminger, Verena Pichler, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 11, 2011
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer
Thomas Wanek, Claudia Kuntner, Jens P Bankstahl, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 26, 2024
First-in-human evaluation of 6-bromo-7-[<sup>11</sup>C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues
Severin Mairinger, Matthias Jackwerth, Zacharias Chalampalakis, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 18, 2009
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET
Claudia Kuntner, Jens P Bankstahl, Marion Bankstahl, et al.
Pharmaceutics
|
December 23, 2022
Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [<sup>11</sup>C]metoclopramide, a PET Probe for P-Glycoprotein Function at the Blood-Brain Barrier
Louise Breuil, Nora Ziani, Sarah Leterrier, et al.
Nuclear Medicine and Biology
|
July 9, 2010
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate
Severin Mairinger, Oliver Langer, Claudia Kuntner, et al.
Molecular Pharmaceutics
|
July 24, 2015
Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography
Thomas Wanek, Kerstin Römermann, Severin Mairinger, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 160) with videos related to
Sort By:
Page
of 16
Molecular Pharmaceutics
|
January 16, 2024
Performance and Sensitivity of [<sup>99m</sup>Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver
Irene Hernández-Lozano, Sarah Leterrier, Severin Mairinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2011
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake
Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 16, 2019
In vivo characterization of [<sup>18</sup>F]AVT-011 as a radiotracer for PET imaging of multidrug resistance
Pavitra Kannan, András Füredi, Sabina Dizdarevic, et al.
Clinical Pharmacology and Therapeutics
|
September 23, 2020
Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects
Martin Bauer, Karsten Bamminger, Verena Pichler, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 11, 2011
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer
Thomas Wanek, Claudia Kuntner, Jens P Bankstahl, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 26, 2024
First-in-human evaluation of 6-bromo-7-[<sup>11</sup>C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues
Severin Mairinger, Matthias Jackwerth, Zacharias Chalampalakis, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 18, 2009
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET
Claudia Kuntner, Jens P Bankstahl, Marion Bankstahl, et al.
Pharmaceutics
|
December 23, 2022
Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [<sup>11</sup>C]metoclopramide, a PET Probe for P-Glycoprotein Function at the Blood-Brain Barrier
Louise Breuil, Nora Ziani, Sarah Leterrier, et al.
Nuclear Medicine and Biology
|
July 9, 2010
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate
Severin Mairinger, Oliver Langer, Claudia Kuntner, et al.
Molecular Pharmaceutics
|
July 24, 2015
Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography
Thomas Wanek, Kerstin Römermann, Severin Mairinger, et al.
Page
of 16